The US Department of Health and Human Services is launching a five-year programme to test faster, more adaptive clinical trials, Axios reports. One of its related projects will use AI to speed up trial-site activation, while the wider effort also targets real-time data analysis and automation.
Watch Desk analysis
What happened
The programme, called SURPASS, will solicit proposals from teams that include a drug sponsor. Selected teams will receive funding and support over five years to test new approaches to clinical trials, according to Axios. The report says proposals will address three areas: trials designed to use fewer patients, analysing data while a trial is under way, and automation to reduce inefficiencies.
Axios also reports that ARPA-H is announcing three related projects. One will use AI to speed up the process of opening clinical-trial sites, including preparing hospitals that have not previously hosted trials. The other projects concern trial-data infrastructure and helping patients with complex cancers use their data and navigate care.
Why it matters
Clinical trials can take years and cost billions to develop a drug, Axios reports. The programme’s practical bet is that better data systems, automation and computational tools can make the process faster or less costly, and potentially let more patients access trials closer to home. Those are goals, not results: the teams have yet to test whether the proposed methods deliver.
The AI element is specific, not a decorative label: it is intended to help prepare and activate trial sites. That could make a difference to where trials can run, though the report does not detail how the system will work or how its performance will be assessed.
Our read
This is a substantial technology-and-policy experiment, not a claim that clinical trials are about to become ten times cheaper. The programme manager cited by Axios said that level of cost reduction was a target, while acknowledging that savings are hard to quantify. The useful question is whether the funded teams produce methods other trial organisers can actually adopt. Faster trials are welcome; fast promises are easier to produce.
What to watch
- Which teams win funding and what trial methods they propose.
- How the AI-assisted site-activation project defines and measures success.
- Whether the programme publishes reusable standards and evidence of reduced costs or timelines.
Discussion spark: If trial sites can be opened faster with AI, what evidence should be required before hospitals and patients rely on the system?
Sources and evidence
- Exclusive: HHS launches project to speed up clinical trials (30 September 2026, 19:00 UTC)
Watch Desk is operated by WittyWires as an independent cross-cutting AI news tracker. It does not speak for the organisations or people it covers.